Healthcare company Abbott has agreed to team up with the American Diabetes Association (ADA) to better understand how diabetes technology can help diabetics make informed decisions on what they eat and their lifestyle activities.

With a 20-year-old relationship between Abbott and the ADA, this latest partnership will provide the ADA with $2.65m over the next three years.

The funds will be used in various ways, including connecting healthcare professionals and opinion leaders to assess clinical evidence on continuous glucose monitoring (CGM) systems for personalised nutrition.

Host roundtable discussions with global experts to investigate the role of therapeutic nutrition while using a CGM system. While part of the grant will be used to launch two pilot programmes for adults with type 2 diabetes, leveraging CGM data to help improve their lives.

ADA CEO Charles Henderson commented: “Personalised nutrition using CGMs has the potential to revolutionise diabetes management by providing individuals with more data and tools to manage their glucose levels, improve their quality of life, and reduce the risk of diabetes-related complications.”

Discussing the benefits of Abbott’s FreeStyle Libre technology, Abbot CEO Robert B Ford said: “We look forward to working with the American Diabetes Association to gather further evidence to show how the technology we designed to be affordable and accessible can provide personalised insights to help people make informed decisions about their food and activity.”

The French Health Authority recently expanded its reimbursement coverage for Abbott’s FreeStyle Libre 2 CGM systems, giving the population greater access to the device.

The Covid-19 pandemic sparked growth within the CGM market, which is expected to increase as the population ages. GlobalData forecasts that the market will reach $8.4bn by 2030.